Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

News

MSc Medical Physics with Radiobiology receives IPEM accreditation

Department Teaching

The Department of Oncology at the University of Oxford is delighted to announce that our new MSc Medical Physics with Radiobiology programme has received Masters Level Accreditation from the Institute of Physics and Engineering Medicine (IPEM).

Image of healthy colon section sourced from VICTOR trial

Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer

Publication Research Tumour Microenvironment

The Oncology Department at the University of Oxford is excited to announce the forthcoming publication in the Proceedings of the National Academy of Sciences (PNAS) of the research paper “Goblet Cell Differentiation Subgroups in Colorectal Cancer.” This groundbreaking study sheds light on the role of goblet cell differentiation in colorectal cancer (CRC) and its impact on cancer progression and prognosis.

DNA (in blue) and the nuclear envelope (in green) found in the nuclei of cancer cells are attacked by the lysosomes (in red) after exposure to chemotherapy drugs as part of the nucleophagy-orchestrated DNA repair process.

Oxford and NTU Singapore Study discovers new process for cells to repair DNA damage

A team of international researchers at the University of Oxford (Oxford) and Nanyang Technological University, Singapore (NTU Singapore), has discovered a new process for repairing damaged DNA that is particularly relevant for patients undergoing colorectal cancer treatments.

Ground-breaking Study reveals previously unknown genetic causes of Colorectal Cancer

Innovation Research Translational Research

A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).

A portrait of Subashan Vadibeler

Subashan Vadibeler wins 2024 Lasker Essay Contest

Awards & Appointments Immunology Publication Research

Subashan Vadibeler, a recent Oxford Rhodes scholar and Department of Oncology student, is one of five co-winners of the international 2024 Lasker Essay Contest, sponsored by the Lasker Foundation.

Picture caption 1: A patient undergoes robot-assisted surgery to remove the prostate in the ProMOTE study

Glowing dye helps surgeons eradicate prostate cancer

Clinical Trials Department Innovation Publication Research Translational Research

A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a study led by the University of Oxford.

Illustration in blue colors of a transparent human body with lungs with cancer cells in red

New funding for development of world's first lung cancer vaccine

Clinical Trials Research Translational Research

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.

Gulnar Abdullayeva receives an Azerbaijan Presidential Award for Youth 2024

Awards & Appointments Research

The HIT-GLIO consortium includes 10 research groups spread across 8 countries all focused on targeting tumour-host interactions in paediatric malignant gliomas to reinvigorate immunity and improve radio- and immunotherapy efficacy.

Prof. Ester Hammond and Dr Monica Olcina travel to Warsaw for the first meeting of the EU Horizon funded consortium – HIT-GLIO

Funding Research Tumour Microenvironment

Researchers develop easy-to-deploy federated learning system that safeguards patient data

Artificial Intelligence Research

The technique, which builds on recent advances in decentralised machine learning, uses inexpensive pre-programmed micro-computers, making it easy to deploy in hospitals and cheap to scale up.

Festive Science Image Competition Winners

Department FLASH Radiation Research

Winners of the Medical Research Foundation's second Festive Science Image Competition, run in partnership with the Medical Research Council (MRC), have been announced today.

Robert Watson Awarded ACP McElwain and Presidents Prize

Awards & Appointments Research

Dr Robert Watson has won one of three McElwain and President's Prizes from the Association of Cancer Physicians for his DPhil work undertaken with Professor Ben Fairfax.

Prof Anna Schuh launches first private specialised haematology clinic and laboratory in sub-Saharan Africa.

Research Translational Research

SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.

Professor Eileen Parkes appointed to lead Oxford’s Experimental Cancer Medicine Centre

Clinical Trials DNA Damage & Repair Immunology Research Translational Research

Eileen Parkes, Associate Professor in Innate Tumour Immunology in the Department of Oncology, will lead the expansion of the centre’s programmes in early drug development and biomarker research.

(A) shows the gene ontology results of genes whose expression and methylation are correlated. The gene ratio refers to the number of genes in that gene set annotated to the GO term divided by the total number of genes in the gene set. A higher gene ratio implies greater over-representation of genes to the particular GO term (B) Genes that were positively correlated with methylation were present more in transcription start sites or promoter regions whereas negatively correlated genes were more enriched in the gene bodies; 3’UTR: 3’ untranslated region, 5’UTR: 5’ untranslated region; TSS1500: 1500 bp upstream of transcription start site, TSS200: 200 bp upstream of transcription start site

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

Publication Research

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

A generic image of a person looking at an x-ray through a magnifying glass.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Clinical Trials Research

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

Clinical Trials Innovation Research Translational Research

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Awards & Appointments Department Innovation Research

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

Hands holding out a paper cut out of lungs

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

Innovation Publication Research

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Mark Hill becomes Fellow of the Institute of Physics and Engineering in Medicine

Awards & Appointments

Dr Mark Hill was awarded the honour of Fellow of the Institute of Physics and Engineering in Medicine (FIPEM) after ‘demonstrating scientific and professional attainment of outstanding merit’.

Load More